Enrollment Complete in RT001 Trial for PSP

  In a recent news release, biopharmaceutical company Retrotope shared that enrollment was complete in its Phase 2 clinical trial. During the trial, researchers will evaluate RT001, a first-in-class oral…

Continue Reading Enrollment Complete in RT001 Trial for PSP

Orphan Drug Designation Granted to TST1001 for Gastric Cancer

The FDA has recently granted Orphan Drug designation to TST1001, Transcenta Holding Limited's monoclonal antibody for gastric cancer/gastroesophageal junction (GC/GEJ). Prior research has demonstrated TST1001's anti-tumor activity, and ongoing research…

Continue Reading Orphan Drug Designation Granted to TST1001 for Gastric Cancer